Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
Stocks · News reference
Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding
Safety and TolerabilityAcross the five active-dose MAD cohorts (n=40), all reported treatment-emergent adverse events (TEAEs) were mild or moderate. There were no severe or serious TEAEs, TEAE-related dose
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed. State Street fell 6.4% after missing sales estimates, while Biomea Fusion, Skydance and other stocks slid premarket.
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $4 price target.
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.